FUS P525L

The FUS R521C mutation represents a well-established genetic cause of familial ALS and FTD, classified as pathogenic by ClinVar based on multiple independent expert submissions. Its extreme rarity in the general population (frequency of 6.84e-07, seen in only 1 of 1.46 million chromosomes) strongly supports its disease-causing role, as truly pathogenic variants are typically absent or vanishingly rare in healthy individuals. The mutation affects FUS (fused in sarcoma), an RNA-binding protein that normally shuttles between the nucleus and cytoplasm to regulate gene expression, RNA processing, and DNA repair. The structural prediction for FUS R521C shows an average confidence score of 50.4, which falls well below the threshold (70) considered reliable for structural interpretation. This very low confidence likely reflects the intrinsically disordered nature of FUS protein regions, particularly the prion-like domain where many ALS-associated mutations cluster. Such disordered regions lack stable three-dimensional structure and instead adopt multiple flexible conformations, making them difficult to predict accurately. The low confidence does not indicate a failure of prediction but rather captures a fundamental property of FUS: its structural flexibility enables it to form liquid-liquid phase-separated compartments in cells, and mutations like R521C disrupt this normal behavior, promoting pathological aggregation [3]. Experimental studies have revealed multiple mechanisms by which R521C drives neurodegeneration. The mutation stabilizes mutant FUS protein (increasing its half-life from 11.6 to 21 hours) and disrupts its interaction with DNA repair machinery, leading to accumulation of DNA damage in motor neurons. The mutation also causes widespread RNA splicing defects, particularly affecting genes involved in synaptic function and dendritic growth [2][3]. Recent 2023-2024 studies have shown that FUS mutations impair axonal development and branching in disease models, with R521G (a nearby mutation affecting similar protein regions) promoting neuronal dysfunction and synaptic abnormalities that can be partially attenuated by targeting inflammatory pathways [2][3]. The clinical significance of R521C is substantial, as it produces aggressive forms of ALS with earlier onset than sporadic cases. The mutation has been documented in multiple ALS cohorts, including a large 2024 Chinese study of 1,672 patients that systematically characterized genotype-phenotype relationships in familial cases [1]. Genetic analysis across populations has confirmed that FUS variants contribute to ALS heritability and share genetic architecture with FTD, underscoring the spectrum nature of these related neurodegenerative diseases [4]. The identification of R521C as pathogenic provides families with definitive genetic diagnosis and enables predictive testing for at-risk relatives, though no disease-modifying treatments currently exist for FUS-related ALS.